GVR Report cover Cancer Immunotherapy Drug Discovery Outsourcing Market Size, Share & Trends Report

Cancer Immunotherapy Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Drug, By Service, By Cancer Type (Lung, Breast, Colorectal, Melanoma, Prostate, Pancreatic), And Segment Forecasts, 2018 - 2025

  • Report ID: GVR-2-68038-646-2
  • Number of Pages: 95
  • Format: Electronic (PDF)
  • Historical Range: 2014 - 2016
  • Industry: Healthcare

Report Overview

The global cancer immunotherapy drug discovery outsourcing market size was valued at USD 617.6 million in 2017. It is poised to register a CAGR of 13.5% during the forecast period. Rising awareness regarding advancements in cancer immunotherapy coupled with increasing investments by pharmaceutical companies in outsourcing is projected to bolster the growth of the market. Pharmaceutical companies are focusing on immunotherapies since they are a potential treatment alternative for cancer owing to their ability to reduce the risk of tumor recurrence, post-chemotherapy.

Expertise in medicine development in specific therapeutic areas and conducting clinical trials across geographies are among the factors supporting the growth of clinical research organizations (CROs). Outsourcing of research activities helps in optimizing funds and time involved in the process. Increasing research and development activities is leading to the faster entry of novel leads in the market.  

China cancer immunotherapy drug discovery outsourcing market

The introduction of advanced therapeutic options such as monoclonal antibodies, cancer vaccines, oncolytic viral therapies, and HDAC inhibitors is anticipated to shape the future of the market. The market being innovation-led, competitive rivalry is increasing with rising demand for products with improved efficacy and reduced side effects. Consequently, substantial investments in R & D in cancer immunotherapy is one of the primary strategies of key players in this market.

Furthermore, there is a growing focus on testing therapeutic options such as checkpoint inhibitors, immunomodulators, tumor-infiltrating lymphocytes (TILs), and chimeric antigen receptor (CAR) T cell therapies for enhanced efficacy. This, in turn, is stoking the growth of the market.

Drug Type Insights

The monoclonal antibodies segment was the most prominent medicine type in 2017. Proved efficacy of monoclonal antibodies and the introduction of enhanced drug types such as bispecific, naked antigen-binding, and conjugated monoclonal antibodies are attracting the attention of pharmaceutical companies.

Cancer vaccines and oncolytic viral therapies are breakthrough innovations in the field of cancer immunotherapy owing to constant R & D efforts of market participants. This immunotherapeutic vaccine includes immune cells of patients converted to dendritic cells by chemical treatment, used against prostate cancer. A few treatment vaccines in the pipeline constitute parts of cells, antigens, and cancer cells.

Therapeutic vaccines have been observed to create anti-cancer antigen acting memory cells in the immune system of the affected individuals. Rising awareness regarding benefits associated with these vaccines has been boosting investments of market players in R & D activities. Therefore, cancer vaccines and oncolytic viral therapies are poised to post the fastest growth over the forecast period.

Growing focus on novel therapeutic options is resulting in the advancement of therapeutic options such as CAR T cell therapies, immune checkpoint inhibitors, and tumor-infiltrating lymphocytes. These therapies are showing promising results in clinical studies of leU.K.emia and lymphomas. However, side effects associated with these therapies such as extremely high fever and life-threatening low blood pressure issues can impede the growth.

Cancer Type Insights

Lung cancer accounted for the leading market share in 2017. Late diagnosis of this condition makes chemotherapy inefficient for the treatment of patients. This drawback can be overcome by immunotherapy as it has proved to have remarkable effects on NSCLC (non-small cell lung cancer) conditions. In addition, the availability of the majority of immunotherapies for NSCLC has been supplementing the growth of the segment.

Ovarian cancer is likely to exhibit the highest CAGR during the forecast period owing to increasing R & D investments and rising prevalence. Immunotherapies have shown positive results in the treatment of ovarian cancer as it enhances the patient’s immune system, in turn, prohibiting the growth of malignant cells. Ovarian oncology’s treatment with immunotherapy includes checkpoint inhibitors and other adoptive therapies. Ongoing R & D in the field has several upcoming potential drugs for the treatment, which will spur the growth of the segment over the forecast period.

Global cancer immunotherapy drug discovery outsourcing market

Immunotherapeutic advancements have been noticed in the case of several other types such as melanoma, head and neck, and prostate cancer. There are 3 immunotherapeutic drugs in the market for head and neck oncology, one target antibody molecule, cetuximab, and two checkpoint inhibitors, nivolumab, and pembrolizumab. Rising prevalence of these cancer types is responsible for encouraging investments in R & D of immunotherapeutic drugs, which in turn is revving up the adoption rate of outsourcing services.

Service Type Insights

Immunotherapy is one of the most promising oncological therapies with advantages such as fewer side effects, higher efficacy, and increased patient convenience over other treatment solutions. As a result, market players are investing heavily in R & D of immunotherapy-based interventions.

The target identification and validation segment dominated the overall market in 2017. It is projected to remain dominant throughout the forecast period. At present, cancer immunotherapy is in its nascent phase. However, the success of currently available immunotherapeutic agents has been drawing the attention of most of the big pharmaceutical companies to invest in new drug development. Thus, the market is anticipated to experience an upthrust with the launch of novel drugs, which is estimated to have a positive impact on early drug discovery procedures in the market.

Currently, only a few drugs are commercially available in immuno-oncology. Drug discovery efforts provide a huge scope for the generation of novel drugs designed for specific targets. Additionally, the trend of outsourcing drug discovery services is rapidly increasing due to factors such as high demand for novel drugs and rising competition among big pharmaceutical companies. Market players are rapidly adopting advanced automation technologies to enhance the quality of services and to reduce turnaround time and operating errors. In addition, automation of the process has significantly reduced the cost of services.

Lead screening procedures are resource and time intensive in nature resulting in demand for developing advanced tools to perform effective assays. These new platforms focus on refining lead selection and optimizing screening procedures with minimal turnaround time. With the introduction of new tools, such as ligand identification and matching software tools, these procedures are progressively becoming less time-consuming and are providing more accurate outputs. Hence, lead screening is expected to emerge as the fastest-growing segment during the forecast period.

Regional Insights

North America held the largest revenue share in the market in 2017. The presence of key CROs and big pharmaceutical and biotech companies has been playing a vital in the growth of the regional market. Surging demand for novel drugs in immunotherapy and increasing outsourcing trend of drug discovery processes are estimated to help the region maintain its position in the global arena through 2025.

Several prominent global market players are headquartered in the U.S. These companies are increasing their global presence by setting up laboratories in Europe and Asia Pacific. These companies have certain advantages such as easy availability of advanced tools used in drug discovery, which enables them to complete the discovery process in a shorter time as compared to their competitors. All these factors have been working in favor of the market in North America.

On the other hand, Asia Pacific is expected to witness lucrative growth during the forecast period. Rising number of CROs offering cost-efficient drug discovery services is likely to contribute to the growth of the regional market.

In addition, compliance with Good Laboratory Practices (GLP) and increasing use of advanced technology is driving the market in the region. Introduction of novel and advanced immunotherapy drugs in China and Japan and ongoing clinical trials and FDA approvals of new molecular entities are also poised to bode well for the market in the region.

Key Companies & Market Share Insights

The market is highly competitive in nature. Key players in the market include Covance, Inc.; Explicyte; Aquila BioMedical; Horizon Discovery Group PLC; Crown Bioscience, Inc.; Promega Corporation; HD Biosciences Co., Ltd.; BPS Bioscience, Inc.; Genscript Biotech Corporation; DiscoverX Corporation; Celentyx Ltd.; ImmunXperts SA; Personalis, Inc.; STC Biologics; and Molecular Imaging, Inc.

Pharmaceutical & biotech companies are increasingly collaborating with academic institutions & non-profit organizations to develop new drugs with improved efficacy. Increasing adoption of advanced treatment options for improved healthcare coupled with the soaring need for optimum capital utilization has been influencing the competitive rivalry in the global arena.

Report Scope



Base year for estimation


Actual estimates/Historical data

2014 - 2016

Forecast period

2018 - 2025

Market representation                                

Revenue in USD Million and CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, U.K., Germany, China, India, Mexico, Brazil, South Africa

Report coverage      

Revenue forecast, company share, competitive landscape, growth factors, and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global cancer immunotherapy drug discovery outsourcing market report based on drug type, service type, cancer type, and region:

  • Drug Type Outlook (Revenue, USD Million, 2014 - 2025)

    • Monoclonal Antibodies

    • Immunomodulators

    • Oncolytic Viral Therapies and Cancer Vaccines

    • Others

  • Service Type Outlook (Revenue, USD Million, 2014 - 2025)

    • Target Identification and Validation

    • Lead Screening and Characterization

    • Cell-Based Assays

  • Cancer Type Outlook (Revenue, USD Million, 2014 - 2025)

    • Lung

    • Breast

    • Colorectal

    • Melanoma

    • Prostate

    • Head and Neck

    • Ovarian

    • Pancreatic

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • The U.S.

      • Canada

    • Europe

      • The U.K.

      • Germany

    • Asia Pacific

      • India

      • China

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.